Refining Precision Prognostics in Multiple Myeloma: Loss of MiR-221/222 Cluster in CD138+ Plasma Cells Results in Short-term Progression and Worse Treatment Outcome

Overview

Journal Blood Cancer J

Date 2025 Mar 16

PMID 40089465

Authors

Konstantinos Soureas

Panagiotis Malandrakis

Maria-Alexandra Papadimitriou

Christos Minopoulos

Ioannis Ntanasis-Stathopoulos

Christine-Ivy Liacos

Maria Gavriatopoulou

Efstathios Kastritis

Meletios-Athanasios Dimopoulos

Andreas Scorilas

Margaritis Avgeris

Evangelos Terpos

Affiliations

Soon will be listed here.

Abstract

The persistence of high relapse rates and therapy resistance continues to challenge the effective management of multiple myeloma (MM). The identification of novel MM-specific molecular markers could ameliorate risk-stratification tools and accurately identify high-risk patients towards personalized prognosis and therapy. miRNA-seq analysis of CD138+ plasma cells (n = 24) unveiled miR-221-3p and miR-222-3p (miR-221/222 cluster) as the most downregulated miRNAs in R-ISS III compared to R-ISS I/II patients. Subsequently, miR-221/222 levels were quantified by RT-qPCR in CD138+ plasma cells of our screening cohort (n = 141), assessing patients' mortality and disease progression as clinical endpoints. Internal validation was performed by bootstrap analysis, while clinical benefit was estimated by decision curve analysis. Kryukov et al. (n = 149) and Aass et al. (n = 86) served as institutional-independent validation cohorts. Loss of miR-221/222 cluster was strongly associated with patients' short-term progression and poor overall survival, which was confirmed by Kryukov et al. and Aass et al. validation cohorts. Intriguingly, miR-221/222-fitted multivariate models offered superior risk-stratification within R-ISS staging and risk-based cytogenetics. Moreover, miR-221/222 loss could effectively discriminate optimal 1st-line treatment responders with inferior treatment outcome. Our study identified the loss of miR-221/222 cluster as a powerful independent predictor of patients' post-treatment progression, ameliorating prognosis and supporting precision medicine in MM.

References

Siegel R, Giaquinto A, Jemal A . Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1):12-49. DOI: 10.3322/caac.21820. View

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

van Nieuwenhuijzen N, Spaan I, Raymakers R, Peperzak V . From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells. Cancer Res. 2018; 78(10):2449-2456. DOI: 10.1158/0008-5472.CAN-17-3115. View

Gkotzamanidou M, Terpos E, Bamia C, Kyrtopoulos S, Sfikakis P, Dimopoulos M . Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis. Leukemia. 2013; 28(5):1113-21. DOI: 10.1038/leu.2013.284. View

Dimopoulos M, Moreau P, Terpos E, Mateos M, Zweegman S, Cook G . Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(3):309-322. DOI: 10.1016/j.annonc.2020.11.014. View

Gonzalez-Calle V, Slack A, Keane N, Luft S, Pearce K, Ketterling R . Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. Ann Hematol. 2018; 97(8):1453-1462. DOI: 10.1007/s00277-018-3316-7. View

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst H, Goldschmidt H, Rosinol L . Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015; 33(26):2863-9. PMC: 4846284. DOI: 10.1200/JCO.2015.61.2267. View

Hagen P, Zhang J, Barton K . High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J. 2022; 12(5):83. PMC: 9151761. DOI: 10.1038/s41408-022-00679-5. View

Ambros V . microRNAs: tiny regulators with great potential. Cell. 2002; 107(7):823-6. DOI: 10.1016/s0092-8674(01)00616-x. View

10.

Ruvkun G . The perfect storm of tiny RNAs. Nat Med. 2008; 14(10):1041-5. DOI: 10.1038/nm1008-1041. View

11.

Gebert L, MacRae I . Regulation of microRNA function in animals. Nat Rev Mol Cell Biol. 2018; 20(1):21-37. PMC: 6546304. DOI: 10.1038/s41580-018-0045-7. View

12.

Bartel D . Metazoan MicroRNAs. Cell. 2018; 173(1):20-51. PMC: 6091663. DOI: 10.1016/j.cell.2018.03.006. View

13.

Papadimitriou M, Panoutsopoulou K, Pilala K, Scorilas A, Avgeris M . Epi-miRNAs: Modern mediators of methylation status in human cancers. Wiley Interdiscip Rev RNA. 2022; 14(2):e1735. DOI: 10.1002/wrna.1735. View

14.

Avgeris M, Panoutsopoulou K, Papadimitriou M, Scorilas A . Circulating exosomal miRNAs: clinical significance in human cancers. Expert Rev Mol Diagn. 2019; 19(11):979-995. DOI: 10.1080/14737159.2019.1673732. View

15.

Papadimitriou M, Papanota A, Adamopoulos P, Pilala K, Liacos C, Malandrakis P . miRNA-seq and clinical evaluation in multiple myeloma: miR-181a overexpression predicts short-term disease progression and poor post-treatment outcome. Br J Cancer. 2021; 126(1):79-90. PMC: 8727627. DOI: 10.1038/s41416-021-01602-8. View

16.

Papadimitriou M, Soureas K, Papanota A, Tsiakanikas P, Adamopoulos P, Ntanasis-Stathopoulos I . miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma. J Transl Med. 2023; 21(1):245. PMC: 10080848. DOI: 10.1186/s12967-023-04034-5. View

17.

Kryukov F, Nemec P, Radova L, Kryukova E, Okubote S, Minarik J . Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. J Transl Med. 2016; 14(1):150. PMC: 4884414. DOI: 10.1186/s12967-016-0906-9. View

18.

Aass K, Nedal T, Bouma S, Tryggestad S, Haukas E, Schmidt Slordahl T . Comprehensive small RNA-sequencing of primary myeloma cells identifies miR-105-5p as a predictor of patient survival. Br J Cancer. 2022; 128(4):656-664. PMC: 9938247. DOI: 10.1038/s41416-022-02065-1. View

19.

Rajkumar S, Dimopoulos M, Palumbo A, Blade J, Merlini G, Mateos M . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-48. DOI: 10.1016/S1470-2045(14)70442-5. View

20.

Rajkumar S . Updated Diagnostic Criteria and Staging System for Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2016; 35:e418-23. DOI: 10.1200/EDBK_159009. View